Derivatization and combination therapy of current COVID-19 therapeutic agents: a review of mechanistic pathways, adverse effects, and binding sites
Fecha
2020Autor
El Kantar, Sally
Nehmeh, Bilal
Saad, Philippe
Mitri, Gabie
Estephan, Celine
Mroueh, Mohamad
Akoury, Elias
Taleb, Robin I.
Documentos PDF
Imagenes y Videos
Resumen
Current treatment of patients with coronavirus 2019 (COVID-19) involves repurposed drugs that inhibit viral infection by
either binding to their respective targets or via modulating cellular signal transduction. However, there is still a great
deal of efficacy enhancement through combination therapy and derivatization. Combination therapy should involve
agents with significant activity and different mechanisms of action. The structural map of the interaction between a drug
and its target protein will help guide drug discovery for devising safe and effective ways to treat COVID-19. Herein, we
report numerous synthetic designs based on enhanced affinity to the viral carbohydrate-rich protein spikes and proteinbinding sites of COVID-19.
Palabras clave
COVID-19; Remdesivir; Hydroxychloroquine; Chloroquine; Favipiravir; Ribavirin; Umifenovir; Lopinavir; Ritonavir; Tocilizumab; Sarilumab; CamostatEnlace al recurso
https://doi.org/10.1016/j.drudis.2020.08.002Colecciones
Estadísticas Google Analytics
Comentarios
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.